The estimated Net Worth of Peter M Neupert is at least $37.3 Milión dollars as of 12 March 2024. Mr. Neupert owns over 15,000 units of Labcorp stock worth over $36,955,624 and over the last 12 years he sold LH stock worth over $0. In addition, he makes $327,366 as Lead Independent Director at Labcorp.
Peter has made over 10 trades of the Labcorp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of LH stock worth $12,600 on 12 March 2024.
The largest trade he's ever made was exercising 100,000 units of Labcorp stock on 13 December 2023 worth over $84,000. On average, Peter trades about 3,948 units every 112 days since 2013. As of 12 March 2024 he still owns at least 169,296 units of Labcorp stock.
You can see the complete history of Mr. Neupert stock trades at the bottom of the page.
Peter M. Neupert serves as Lead Independent Director of the Company. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) since December 2013 and currently serves as the Lead Independent Director. He is also a Director of Clinithink Ltd. and Navigating Cancer Inc. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc. (NASDAQ: NXGN) from August 2013 to January 2014 and Freedom Innovations LLC from May 2013 to April 2016. He serves as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. Mr. Neupert serves as the Board’s Lead Independent Director and brings a deep understanding of the role of the Board and its oversight of corporate governance and business strategy.
As the Lead Independent Director of Labcorp, the total compensation of Peter Neupert at Labcorp is $327,366. There are 10 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.
Peter Neupert is 64, he's been the Lead Independent Director of Labcorp since 2019. There are 3 older and 22 younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.
Peter's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.
Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong a David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.
recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.
Labcorp executives and other stock owners filed with the SEC include: